Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Agrippal S1 in Vietnamese Volunteers
NCT01123954Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Agrippal S1 in influenza, sponsored by Novartis. Primary endpoint: Adverse Events at 30 days. Started Jan 2010; status: completed.
02
Drugs
Agrippal S1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01123954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01123954.